We note that, to our knowledge, this is one of the first reports describing morphologic switching from adenocarcinoma to sarcomatoid cancer with an epithelial‐to mesenchymal transition (EMT) mechanism in a patients with KRAS G12C–mutant NSCLC who was undergoing sotorasib therapy. Here, KRAS is linked to adenocarcinoma.